Navigation Links
Cleveland Clinic Recognizes Circulating Tumor Cell Technology as Top Medical Innovation for 2009
Date:11/12/2008

RARITAN, N.J., Nov. 12 /PRNewswire/ -- Veridex, LLC announced today that the technology used in the CellSearch(R) System to measure circulating tumor cells (CTCs) was ranked as the top medical innovation for 2009 by the Cleveland Clinic, a leading multispecialty academic medical center. The ranking is based on technologies likely to have a significant impact on health care next year.

The prestigious annual recognition follows a rigorous selection process by a panel of Cleveland Clinic physicians. The list was announced today at the Cleveland Clinic's 2008 Innovation Summit.

To view the multimedia news release, go to: http://www.nnpkit.com/veridex/cellsearch/.

"We are deeply gratified by this recognition from the Cleveland Clinic," said Robert McCormack, Ph.D., Vice President of Medical and Scientific Affairs, Veridex. "Our entire team is committed to the research and development of this technology, and our goal with the CellSearch(R) test is to provide patients and doctors with reliable and timely information about cancer progression."

CellSearch(R), a proprietary Veridex technology, is cleared by the U.S. Food and Drug Administration (FDA) to predict progression-free survival (PFS) and overall survival (OS) in patients with metastatic breast, colorectal or prostate cancer. The test can be used at any time during the course of disease for serial monitoring of patients with these types of cancer. The CellSearch(R) System is also available as a diagnostic test in Europe.

The CellSearch(R) System is the first diagnostic test to automate the capture and detection of tumor cells that have detached from solid tumors and entered the patient's blood. With the CellSearch(R) System, it is possible to reproducibly find a single circulating tumor cell among approximately 40 billion blood cells in a 7.5 mL blood sample.

The ability to identify a single cancer cell through this innovative technology provides physicians with an important measure of a patient's disease prognosis to help them make more informed patient care decisions. Dr. Mark Graham, a practicing oncologist from Waverly Hematology Oncology in Cary, North Carolina, has used CellSearch(R) for the past two years to regularly monitor the prognosis of his population of metastatic breast cancer patients.

"Knowing a patient's CTC count provides a second measurement, complementary to traditional imaging, to help me assess the prognosis of a patient and gauge her response to current treatment. This allows my team to better advise patients of their current status and make more informed treatment decisions. Many of my patients find that the CellSearch(R) CTC test allows them to continue their daily activities with the peace of mind that I am closely monitoring their disease and will be able to adjust their treatment in a timely fashion, if necessary," says Dr. Graham.

Dr. Graham adds, "Our general impression is that the CellSearch(R) test has allowed us to do fewer radiology imaging studies, which can reduce cost, lessen radiation exposure and save valuable time for the patient."

Last year, another Veridex diagnostic test, the GeneSearch(TM) Breast Lymph Node Assay, was recognized by TIME magazine as one of the top medical breakthroughs of 2007. This assay is a diagnostic test indicated to detect lymph node metastases in breast cancer.

About CellSearch(R)

The CellSearch(R) test works by using antibodies that are joined to microscopic iron particles, called ferrofluid. These antibody/ferrofluid combinations attach very specifically to CTCs. Powerful magnets then draw the CTCs out of the blood sample and they are then stained with additional bio-molecules and chemicals so that they can be positively identified as CTCs.

About Veridex, LLC

Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value in vitro diagnostic oncology products. Veridex's products may significantly benefit patients through earlier disease detection and may enable personalized strategies to help improve patient management and outcomes. For more information, visit http://www.veridex.com.


'/>"/>
SOURCE Veridex, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NanoMedicine Summit Returns to Cleveland, September 25-26
2. University Hospitals Case Medical Center, Cleveland, USA and Cardialysis BV, Rotterdam, the Netherlands Enter Strategic Alliance to Found Cardialysis Cleveland
3. Cleveland Clinic and Rutgers to Lead Newly Formed Institute for War Wounded
4. Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS
5. Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007
6. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
7. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
8. Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans
9. CorMatrix Announces Pre-Clinical Data Suggesting Next Generation ECM Technology(TM) Can Improve Cardiac Function
10. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
11. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the ... at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application ... team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
Breaking Biology News(10 mins):